
Opinion|Videos|December 21, 2024
Clinical Value of Biosimilars and the Role of Interchangeability
A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs for patients and the healthcare system in general. Given that, why do you think the uptake of biosimilars is still relatively low?
- How can the uptake of biosimilars into health systems be improved?
- Interchangeability can be employed by pharmacists to switch a reference product with a biosimilar. What are your best practices for employing this in your practice?
- What has your experience been like switching from adalimumab reference product to biosimilars?
- How can switching from adalimumab reference product to biosimilars be improved in the future?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5